Literature DB >> 1642641

Effect of age and gender on the activity of human hepatic CYP3A.

C M Hunt1, W R Westerkam, G M Stave.   

Abstract

Many pharmacokinetic investigations in the elderly population reveal decreased clearance of lipophilic drugs metabolized by the cytochrome P450 enzymes; however, few studies have evaluated aging-dependent or gender-related changes in specific cytochrome P450 enzymes. The clearance of quinidine, midazolam, triazolam, erythromycin, and lidocaine declines with age; these drugs are metabolized by the isoform, CYP3A. To determine whether these metabolic effects are due to changes in CYP3A, the effects of age and gender on CYP3A activity were examined. The activity of the human hepatic cytochrome P450, CYP3A, was quantified in vitro as erythromycin N-demethylation in microsomes prepared from forty-three resected human liver specimens obtained from patients, age 27 to 83, with normal liver function. Erythromycin N-demethylation varied 5-fold in human liver microsomes. CYP3A activity was 24% higher in females than males (P = 0.027). CYP3A activity did not correlate with age, smoking status, ethanol consumption or percent ideal body weight. Large interindividual differences and a small female-specific increase in CYP3A activity were obtained. However, CYP3A activity was unaffected by age over the range of 27-83 years, suggesting that the aging-related alteration in the clearance of CYP3A substrates is secondary to changes in liver blood flow, size, or drug binding and distribution with aging.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1642641     DOI: 10.1016/0006-2952(92)90010-g

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  88 in total

Review 1.  Drug interactions and the statins.

Authors:  R J Herman
Journal:  CMAJ       Date:  1999-11-16       Impact factor: 8.262

2.  The effects of an oral contraceptive containing ethinyloestradiol and norgestrel on CYP3A activity.

Authors:  Donna J Belle; John T Callaghan; J Christopher Gorski; Juan F Maya; Omiema Mousa; Steven A Wrighton; Stephen D Hall
Journal:  Br J Clin Pharmacol       Date:  2002-01       Impact factor: 4.335

3.  Sex and age differences in the pharmacokinetics of alosetron.

Authors:  K M Koch; J L Palmer; N Noordin; J J Tomlinson; C Baidoo
Journal:  Br J Clin Pharmacol       Date:  2002-03       Impact factor: 4.335

4.  Fulminant hepatic failure associated with triazolam.

Authors:  Tatsuo Kanda; Osamu Yokosuka; Keiichi Fujiwara; Hiromitsu Saisho; Hidetoshi Shiga; Shigeto Oda; Keiko Okuda; Yasuhiko Sugawara; Masatoshi Makuuchi; Hiroyuki Hirasawa
Journal:  Dig Dis Sci       Date:  2002-05       Impact factor: 3.199

Review 5.  Sex differences in transplantation.

Authors:  Jeremiah D Momper; Michael L Misel; Dianne B McKay
Journal:  Transplant Rev (Orlando)       Date:  2017-02-20       Impact factor: 3.943

Review 6.  Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications.

Authors:  A A Mangoni; S H D Jackson
Journal:  Br J Clin Pharmacol       Date:  2004-01       Impact factor: 4.335

7.  CYP3A phenotypes and genotypes in North Indians.

Authors:  Naushad Rais; Yogesh K Chawla; Krishan K Kohli
Journal:  Eur J Clin Pharmacol       Date:  2006-04-21       Impact factor: 2.953

8.  Effects of gender and age on serum concentrations of antidepressants under naturalistic conditions.

Authors:  S Unterecker; P Riederer; F Proft; J Maloney; J Deckert; B Pfuhlmann
Journal:  J Neural Transm (Vienna)       Date:  2012-12-20       Impact factor: 3.575

Review 9.  Drug dosage in the elderly. Is it rational?

Authors:  K Turnheim
Journal:  Drugs Aging       Date:  1998-11       Impact factor: 3.923

Review 10.  Calcium antagonists in the elderly. A risk-benefit analysis.

Authors:  J B Schwartz
Journal:  Drugs Aging       Date:  1996-07       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.